Endobronchial Ultrasound Biopsy Market Report 2026

The endobronchial ultrasound biopsy market size has grown strongly in recent years. It will grow from $0.66 billion in 2025 to $0.71 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising prevalence of lung cancer cases, increasing adoption of minimally invasive diagnostic procedures, growth in hospital-based bronchoscopy units, advancements in ultrasound-guided biopsy technologies, expanding awareness of early thoracic disease diagnosis.

The endobronchial ultrasound biopsy market size is expected to see strong growth in the next few years. It will grow to $0.93 billion by 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing demand for precision-guided pulmonary diagnostics, growing adoption of single use biopsy devices, expansion of AI-enabled bronchoscopy imaging systems, rising investments in cancer diagnostic infrastructure, increasing utilization of outpatient and ambulatory biopsy procedures. Major trends in the forecast period include increasing adoption of minimally invasive mediastinal biopsy procedures, rising preference for single use endobronchial ultrasound devices, growing demand for real-time lymph node sampling accuracy, expansion of lung cancer screening and diagnostic programs, increasing use of advanced ultrasound-guided peripheral lung lesion localization.

The rising incidence of lung cancer is expected to propel the growth of the endobronchial ultrasound biopsy market going forward. Lung cancer is a type of malignant tumor characterized by uncontrolled and abnormal cell proliferation in lung tissues that can invade nearby structures or metastasize to distant organs. The increasing incidence of lung cancer is contributing to multiple risk factors such as higher smoking prevalence and environmental exposures that elevate the likelihood of lung malignancies. Endobronchial ultrasound biopsy is supporting precise and minimally invasive sampling of lung and mediastinal tissues, thereby enabling accurate diagnosis, staging, and monitoring of lung cancer, which further contributes to guiding targeted treatment decisions and improving patient outcomes. For instance, in March 2026, according to the Cancer Research UK (CRUK), a UK-based Cancer Research UK (CRUK), for women in the UK, the European age-standardised (AS) incidence rate of lung cancer is projected to increase by 2% between 2024-2026 and 2038-2040, rising from approximately 75.8 to 77.6 cases per 100,000 women per year. Therefore, the increasing incidence of lung cancer is propelling the growth of the endobronchial ultrasound biopsy market.

Leading companies operating in the endobronchial ultrasound biopsy market are focusing on developing innovative products such as next-generation EBUS bronchoscopes to enhance diagnostic accuracy and improve minimally invasive lung cancer procedures. Next-generation EBUS bronchoscopes are advanced endoscopic devices with integrated high-resolution ultrasound probes that allow real-time imaging of airways and lymph nodes, helping clinicians perform more precise, minimally invasive lung biopsies compared to traditional bronchoscopes. For example, in September 2025, Olympus Corporation, a Japan-based medical technology company, launched the BF-UC190F EBUS bronchoscope, an innovative device designed to improve diagnostic accuracy and procedural efficiency in thoracic oncology. The BF-UC190F features a thinner, more flexible insertion tube, a high-resolution ultrasound probe, and enhanced maneuverability, enabling clinicians to access difficult-to-reach lymph nodes while reducing patient discomfort. Its ergonomic design and improved imaging capabilities support safer, faster biopsies and reduce the need for repeat procedures. This advanced bronchoscope is particularly beneficial in early lung cancer detection and staging, offering real-time guidance for needle aspiration and tissue sampling.

In February 2025, Micro-Tech (Nanjing) Co. Ltd., a China-based healthcare technology company, acquired Creo Medical S. L. U. (CME) for an undisclosed amount. With this acquisition, Micro-Tech (Nanjing) Co., Ltd. aims to expand its global footprint and strengthen its distribution network across Europe by leveraging CME’s established sales channels and complementary product portfolio. Creo Medical S. L. U. (CME) is a Spain-based healthcare technology company specializing in endobronchial ultrasound biopsy solutions.

Major companies operating in the endobronchial ultrasound biopsy market are Medtronic plc, Siemens Healthcare Private Limited, FUJIFILM Holdings Corporation, Koninklijke Philips N. V., GE HealthCare Technologies Inc., Boston Scientific Corporation, Konica Minolta Inc., Intuitive Surgical Inc., Olympus Corporation, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., STERIS plc, Teleflex Incorporated, Canon Medical Systems Corporation, Cook Group Incorporated, CONMED Corporation, PENTAX Medical, Esaote S. p. A., Medi-Globe Technologies GmbH, ENDO-FLEX GmbH, Taewoong Medical Co. Ltd., ACE Medical Devices Private Limited, Body Vision Medical Ltd., Clinodevice S. r. l.

North America was the largest region in the endobronchial ultrasound biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endobronchial ultrasound biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the endobronchial ultrasound biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endobronchial ultrasound biopsy market consists of revenues earned by entities by providing services such as diagnostic tissue sampling, lymph node staging, real-time ultrasound imaging, procedure planning and guidance, and post-procedural analysis and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The endobronchial ultrasound biopsy market also includes sales of needle adapters, ultrasound processors, light sources, video processors, monitor systems, guide sheaths, disposable biopsy forceps, and cytology brushes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.